A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Clinical trial NCT03439280 · COMPLETED
Trial details
- NCT number
- NCT03439280
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-20
- Primary completion
- 2022-01-28
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.